Stereotaxis (STXS)
:STXS
Want to see STXS full AI Analyst Report?
Top Page
Stereotaxis
(STXS)
Select Model
Select Model
Rating:49Neutral
Price Target:
$2.00
▼(-1.48% Downside)
Action:Reiterated
Date:05/16/26
The score is held back primarily by weak financial performance (large operating losses and sustained cash burn) and a technically weak price trend below major moving averages. These are partially offset by constructive earnings-call signals—reiterated >$40M FY2026 guidance, recent FDA approvals, and early evidence of higher-margin disposable revenue potential—though near-term execution and cash-flow risks remain significant.
Positive Factors
Regulatory approvals expanding addressable market
Multiple recent FDA approvals (PMA for MAGIC, clearance for Synchrony, Genesys X clearance and approvals in Europe/China) establish a regulatory foundation for a broader product ecosystem. This durable credential reduces regulatory tail risk, opens new geographies and use-cases, and materially expands long-term commercial opportunity for capital and consumable sales.
Negative Factors
Sustained negative free cash flow
Large negative operating and free cash flow is a durable structural risk: ongoing cash burn requires external financing or rapid operational improvement. Until recurring disposable revenue materially scales, the firm faces funding pressure which can force dilution, constrain investments, or slow commercialization over the next several quarters.
Read all positive and negative factors
Positive Factors
Negative Factors
Regulatory approvals expanding addressable market
Multiple recent FDA approvals (PMA for MAGIC, clearance for Synchrony, Genesys X clearance and approvals in Europe/China) establish a regulatory foundation for a broader product ecosystem. This durable credential reduces regulatory tail risk, opens new geographies and use-cases, and materially expands long-term commercial opportunity for capital and consumable sales.
Read all positive factors
Stereotaxis (STXS) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$193.52M
Dividend YieldN/A
Average Volume (3M)583.61K
Price to Earnings (P/E)―
Beta (1Y)0.83
Revenue Growth13.40%
EPS Growth20.97%
CountryUS
Employees139
SectorHealthcare
Sector Strength45
IndustryMedical - Instruments & Supplies
Share Statistics
EPS (TTM)-0.25
Shares Outstanding97,736,700
10 Day Avg. Volume380,338
30 Day Avg. Volume583,610
Financial Highlights & Ratios
PEG Ratio0.58
Price to Book (P/B)11.17
Price to Sales (P/S)6.46
P/FCF Ratio-15.18
Enterprise Value/Market Cap0.95
Enterprise Value/Revenue5.90
Enterprise Value/Gross Profit10.96
Enterprise Value/Ebitda-9.43
Forecast
1Y Price Target
$4.13Price Target Upside103.20% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-0.18
Revenue Forecast (FY)$39.40M
Stereotaxis Business Overview & Revenue Model
Company Description
Stereotaxis, Inc. designs, manufactures, and markets robotic systems, instruments, and information systems for the interventional laboratory in the United States and internationally. Its robotic magnetic navigation (RMN) systems include the Genesi...
How the Company Makes Money
Stereotaxis makes money primarily by selling and supporting its robotic magnetic navigation ecosystem used in hospital electrophysiology labs. Key revenue streams typically include: (1) Capital equipment sales: one-time (or milestone-based) revenu...
Stereotaxis Earnings Call Summary
Earnings Call Date:May 12, 2026
(Q1-2026)
| % Change Since: |
Next Earnings Date:Aug 11, 2026
Earnings Call Sentiment Positive
The call balanced transformational strategic progress with near-term execution and financial headwinds. Major positives include multiple recent FDA approvals (MAGIC, Synchrony), successful early clinical use of the MAGIC catheter, a clear disposable revenue opportunity (disposables often >$5k–$8k per procedure), Genesys X and Synchrony commercialization steps, and the Robocath acquisition that strengthens long-term robotics strategy. Offsetting these are short-term declines in reported revenue (Q1 revenue down ~16%), capacity constraints and supply transition issues due to winding down the Johnson & Johnson relationship, continued operating losses, and increasing negative free cash flow. Management reiterated >$40M revenue guidance for 2026 and described a path to ramp and profitability, but achieving that depends on manufacturing ramp, adoption of disposables, and execution of capital sales.Positive Updates
Major Regulatory Approvals
Received multiple recent regulatory approvals including 4 U.S. FDA approvals in recent months (PMA for MAGIC in January; FDA clearance for Synchrony last month), plus approvals in Europe and China. Genesys X previously received FDA clearance. These approvals create a new foundational ecosystem of products and materially expand the company's addressable market.
Negative Updates
Quarterly Revenue Decline
Q1 2026 revenue was $6.3 million versus $7.5 million in Q1 2025, a decline of approximately 16.0%. System revenue fell from $2.0 million to $1.3 million (-35.0%) and recurring revenue declined from $5.5 million to $5.0 million (-9.1%).
Read all updates
Q1-2026 Updates
Positive
Negative
Major Regulatory Approvals
Received multiple recent regulatory approvals including 4 U.S. FDA approvals in recent months (PMA for MAGIC in January; FDA clearance for Synchrony last month), plus approvals in Europe and China. Genesys X previously received FDA clearance. These approvals create a new foundational ecosystem of products and materially expand the company's addressable market.
Read all positive updates
Company Guidance
Management reiterated guidance for double‑digit revenue growth in FY2026 with annual revenue expected to surpass $40 million, ramping sequentially each quarter and with both Q3 and Q4 forecasted to exceed $10 million; they also expect at least $3 million of Synchrony revenue this year and to establish at least five active Genesis programs. Operational targets include ramping MAGIC catheter production to about 500 units per month by year‑end and capturing disposable revenue per procedure already >$5,000 and often >$8,000 (including a recent $100,000 hospital disposables order for a month). Quarterly and balance‑sheet metrics cited alongside the guidance were Q1 revenue of $6.3 million (system $1.3M, recurring $5.0M), gross margin 60% (recurring 66%, system 39%), operating loss $6.0M (net loss $5.9M), adjusted operating loss $2.9M, negative free cash flow $3.5M, and cash of $14.6M with no debt; management said operating losses should decline as recurring revenue grows and that they can integrate Robocath and fund the ramp without substantial dilution.Stereotaxis Financial Statement Overview
Summary
Income Statement
23
Negative
Balance Sheet
54
Neutral
Cash Flow
18
Very Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 31.20M | 32.38M | 26.92M | 26.77M | 28.15M | 35.02M |
| Gross Profit | 16.80M | 17.07M | 14.59M | 14.86M | 18.47M | 23.23M |
| EBITDA | -19.53M | -20.56M | -23.77M | -21.24M | -18.35M | -12.78M |
| Net Income | -21.68M | -21.64M | -24.05M | -20.71M | -18.29M | -10.72M |
Balance Sheet | ||||||
| Total Assets | 54.03M | 52.25M | 46.72M | 41.91M | 53.41M | 60.98M |
| Cash, Cash Equivalents and Short-Term Investments | 14.62M | 13.42M | 12.22M | 19.82M | 28.43M | 38.74M |
| Total Debt | 5.28M | 5.44M | 6.01M | 5.49M | 5.86M | 6.11M |
| Total Liabilities | 34.43M | 33.53M | 35.29M | 19.99M | 21.48M | 21.56M |
| Stockholders Equity | 19.60M | 18.72M | 11.43M | 21.92M | 31.93M | 39.42M |
Cash Flow | ||||||
| Free Cash Flow | -15.52M | -13.78M | -8.53M | -9.51M | -10.79M | -4.34M |
| Operating Cash Flow | -15.35M | -13.69M | -8.50M | -9.14M | -8.41M | -2.95M |
| Investing Cash Flow | -172.00K | -93.00K | 74.00K | 19.77M | -22.09M | -1.40M |
| Financing Cash Flow | 19.45M | 14.76M | 297.00K | 81.00K | 220.00K | 547.00K |
Stereotaxis Technical Analysis
Neutral
2.03
Price Trends
1.90
Positive
2.08
Negative
2.40
Negative
Market Momentum
0.02
Negative
54.37
Neutral
82.93
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For STXS, the sentiment is Neutral. The current price of 2.03 is above the 20-day moving average (MA) of 1.91, above the 50-day MA of 1.90, and below the 200-day MA of 2.40, indicating a neutral trend. The MACD of 0.02 indicates Negative momentum. The RSI at 54.37 is Neutral, neither overbought nor oversold. The STOCH value of 82.93 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for STXS.
Stereotaxis Risk Analysis
Stereotaxis disclosed 57 risk factors in its most recent earnings report. Stereotaxis reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Stereotaxis Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
72 Outperform | $2.16B | 34.58 | 16.19% | 0.95% | 13.27% | 36.99% | |
68 Neutral | $3.76B | 26.93 | 8.95% | ― | 11.34% | 12.26% | |
66 Neutral | $1.40B | -291.18 | -0.95% | ― | 15.01% | 88.10% | |
58 Neutral | $1.49B | -70.93 | -6.07% | ― | 4.03% | 70.55% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | $193.52M | -9.03 | -153.21% | ― | 13.40% | 20.97% | |
49 Neutral | $34.09M | -6.95 | -166.28% | ― | 3.37% | 15.78% |
* Healthcare Sector Average
STXS
Stereotaxis
1.98
-0.25
-11.21%
ATRC
Atricure
27.67
-6.33
-18.62%
LMAT
Lemaitre Vascular
94.65
14.98
18.81%
MMSI
Merit Medical Systems
63.06
-30.58
-32.66%
STAA
Staar Surgical
29.89
13.20
79.09%
MLSS
Milestone Scientific
0.39
-0.57
-59.43%
Stereotaxis Corporate Events
Executive/Board ChangesShareholder Meetings
Stereotaxis Shareholders Endorse Board, Auditor and Compensation
Positive
May 15, 2026
On May 14, 2026, Stereotaxis held its Annual Meeting of Shareholders with approximately 65.34% of the 121,182,983 total voting power represented, satisfying quorum requirements. Shareholders voted on the election of three Class I directors to serv...
Business Operations and StrategyM&A Transactions
Stereotaxis to Acquire Robocath in Strategic Robotics Deal
Positive
Apr 15, 2026
On April 14, 2026, Stereotaxis agreed to acquire 100% of French robotic cardiology innovator Robocath in a deal expected to close in July 2026, subject to debt restructuring, French regulatory clearance, and other customary conditions. The upfront...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.